Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy

Shuyan Han, Jun Wu

School of Biomedical Engineering, Sun Yat-sen University, Shenzhen, 518057, China

ARTICLE INFO

Keywords:
Three-dimensional (3D) Scaffolds
Hydrogels
Macroscale

ABSTRACT

Though increasing understanding and remarkable clinical successes have been made, enormous challenges remain to be solved in the field of cancer immunotherapy. In this context, biomaterial-based immunomodulatory strategies are being developed to boost antitumor immunity. For the local immunotherapy, macroscale biomaterial scaffolds with 3D network structures show great superiority in the following aspects: facilitating the encapsulation, localized delivery, and controlled release of immunotherapeutic agents and even immunocytes for more efficient immunomodulation. The concentrating immunomodulation in situ could minimize systemic toxicities, but still exert abscopal effects to harness the power of overall antitumor immune response for eradicating malignancy. To promote such promising immunotherapies, the design requirements of macroscale 3D scaffolds should comprehensively consider their physicochemical and biological properties, such as porosity, stiffness, surface modification, cargo release kinetics, biocompatibility, biodegradability, and delivery modes. To date, increasing studies have focused on the relationships between these parameters and the biosystems which will guide/assist the 3D biomaterial scaffolds to achieve the desired immunotherapeutic outcomes. In this review, by highlighting some recent achievements, we summarized the latest advances in the development of various 3D scaffolds as niches for cancer immunotherapy. We also discussed opportunities, challenges, current trends, and future perspectives in 3D macroscale biomaterial scaffold-assisted local treatment strategies. More importantly, highlighting some recent achievements, we summarized the latest advances in the development of various 3D scaffolds as niches for cancer immunotherapy. We also discussed opportunities, challenges, current trends, and future perspectives in 3D macroscale biomaterial scaffold-assisted local treatment strategies. More importantly, this review put more efforts to illustrate how the 3D biomaterial systems affect to modulate antitumor immune activities, where we discussed how significant the roles and behaviours of 3D macroscale scaffolds towards cancer immunotherapy in order to direct the design of 3D immunotherapeutic.

1. Introduction

Since the secrets of immunosuppressive tumor microenvironment (TME) in most cancer patients uncovered, cancer immunotherapy has caught extensive attention and run to the frontier that revolutionized the traditional cancer therapies. Cancer immunotherapy aims to intervene the immune systems, fully evoking host immunity or initiatively manipulating immune activities, to combat tumor cells and even eradicate the malignancies [1,2]. The cancer immunotherapy could likely restrain cancer metastasis and relapse for a long term. However, despite many exceptional advances, in most cases, its therapeutic efficacy towards many different cancer types in clinic is mainly limited [3]. Except the suboptimal patient immune response rate curtailling the therapeutic efficiency, some common immune-associated side effects such as autoimmune reactions, cytokine release syndrome, and vascular leak syndrome severely challenge the safety of this treatment [4]. Besides, major cancer immunotherapies were primarily applied only in hematological malignancies but still unable to break through the tough barriers in solid tumors [4]. And some problems also remain in the current approaches like adoptive cell transfer (ACT) strategies of ex vivo cell expansion, involving the generation of low-quality T cells without sustained persistence and minimal adverse toxicity [5].

Multifunctional biomaterial-based drug delivery system (DDS) strategies provide much more feasibility and selectivity to address the limitations in cancer immunotherapy [6,7]. Novel smart delivery systems can effectively payload, efficiently protect the immunotherapeutic cargos and control their fate in designate spatiotemporal manner to increase the target and accumulation within tumors and/or immunocytes of interest, weaken the off-target effects and systemic toxicity [8–11]. Many promising nanoscale and microscale biomaterial-based immunomodulatory strategies reported and reviewed elsewhere...
exemplify the exploration for well-designed cancer immunotherapy [12–14]. Based on the specificity of the cancer cells and TME, nano- materials for immunotherapy can positively and precisely target the cancer site by modifying targeted molecules, achieve controllable and sustained treatments on demand by inserting smart response “switches” (chemical bonds or functional groups, etc). To some extent, they did resolve few of the abovementioned obstacles during immunotherapy [15–18]. Nevertheless, recent evidence has pointed to non-negligible systemic toxicity and a small percentage lower than 1% tumor accumulation of nanoparticle agents via traditional bolus administration [3, 19]. It makes most of micro- and nano-scale drug delivery biomaterials difficult to show satisfactory results in clinics.

Compared to nano and micro biomaterials, the bulk 3D biomaterial platforms show some extraordinary superiorities [20–22]. Aside from excellent biocompatibility and environmental responsiveness, they have many unique features including macroscale volume, 3D porous inner structures, swelling properties, flexibility, and elasticity. These merits will expand the practical applications of cancer immunotherapy. On the one hand, the macroscale injections and implants could be positioned in situ at the specific space for regional therapies reducing toxicity related to the systematic administration. Their adaptive shapes better fit irregular lesions. The localized delivery of pharmaceuticals tends to result in magnified immunotherapy at lower per dosage. On the other hand, these macroscale 3D counterparts usually have physiological biomimetic matrix which could act as artificial immune tissues for recruiting, housing, and programming host immunocytes or cell incubation depots for encapsulating, proliferating, modulating engineered immunocytes [23,24]. Currently, 3D scaffold biomaterials have already applied in various applications including tumor immunotherapy, tissue engineering, bone related diseases, infectious diseases, and many others [25–28].

Injectable or implantable hydrogels and scaffolds, representative of 3D macroscale biomaterials, facilitate the controlled delivery and release of therapeutic small molecule reagents, macromolecule biological factors, and even living cells strikingly heightening the vitality of cancer immunotherapy [29]. Unfortunately, clinical translations of 3D macroscale biomaterial-based immunotherapies still develop in a slow graded pace during several decades [30,31]. More and more widely recognized, it is essential for the biomaterial engineering researchers to attain a systematic characterization and comprehensive understanding of the mutual interaction between biomaterials and immune system, including how the physicochemical and mechanical properties of the particular biomaterial system influence the immunologic behaviours, and how immunologic indexes fluctuate towards different biomaterial systems upon timescales, in order to speed up their clinical developments [7,32,33] (Fig. 1).

In this review, the importance of 3D macroscale biomaterial-based cancer immunotherapy will be fully introduced. Firstly, the cancer immunotherapy will be briefly summarized about its principles, mechanisms with some typical methods or techniques. According to existing clinical failures and dilemmas of cancer immunotherapy, the problems and challenges of cancer immunotherapy faced nowadays will be raised. Subsequently, biomaterial-based strategies with a bright prospect to improve the immunotherapeutic effects will be put forward in which the notable advantages of 3D macroscale biomaterials would be highlighted. Due to the indispensability but lack of studies on the relationships between material properties and their behaviours and interactions with the biosystems, this review will put more efforts to profile different properties of macroscale biomaterials influence their functions as immunotherapeutic niches. And the following part will introduce the latest successful trials of 3D macroscale biomaterials for enhanced precise immunotherapy. Finally, the emerging trends together with challenges for future cancer immunotherapies will be critically discussed.
2. Tumor immunotherapy and 3D scaffold biomaterials: a brief summary

The tumor-imposed immunosuppression is the reason why immune cells scarcely traffic into TME and take actions for immune attacks. The macroscale 3D scaffold-based immunotherapies would help to tip the balance. With the supply of certain matrixes, the immune events can be rearranged to disturb the immune tolerance by imported immunomodulatory molecules or cells or just scaffolds themselves. It will enhance various functions like peripheral programming of immune cells, intratumoral recruiting of effector cells, etc. The strategies based on this kind of materials have shown increasing merits in cancer immunotherapy and preclinical research. In this section, brief introduction of cancer immunobiology (e.g., tumor immune microenvironment modulation, tumor-targeted systematic immune programming) paired with the significance of auxiliary from 3D biomaterials for cancer.

Fig. 1. Versatile 3D macroscale biomaterial scaffolds equipped with multiple personalities meeting a variety of needs in tumor immune treatments.

Fig. 2. 3D macroscale biomaterial-based tumor immune microenvironment modulation. (ICB: immune checkpoints blockade; ACT: adoptive cell transfer; dLN: draining lymph node.)
immunotherapy will be initially summed up (Fig. 2).

2.1. Immuno-oncology and current tumor immunotherapy

Before launching into biomaterials, tumor immunology and cancer immunotherapy should be grasped in the first place. Since the confirmation of the role immune system playing in tumor progress a century ago, the viewpoints of cancer nature have been gradually shifted that tumors are no longer merely deemed as crowds of aberrant cells, but as a systemic chaos. The interactions between cancer cells and immunity take place throughout the course of tumor development [34]. The major function of the immune system is to detect threat, sustain homeostasis, and provide precise immunological memory to resist a second invasion. During the period of cancer primary pathological stage, the immune surveillance and immune clearance from the T cells, NK cells and some other immunocytes function [35]. After the endless immune editing improving the immune resistance, the immune escape of tricky cancer cells accelerates their survival and proliferation.

A variety of factors create favourable circumstances for that immunosuppression. First, tumor cells manage to display weak immunogenicity by down-regulating the expression of tumor antigens; releasing soluble antigen molecules to induce tumor antibodies binding to tumor antigens; reducing the expression of major histocompatibility complex (MHC)-1 proteins limiting efficient antigen presentation; decreasing the secretion of antigen presentation costimulatory factors, etc. The over-riding outcome is a significant drop in the amount of recognition of immune cells [36,37]. Second, tumor cells continue to target the immune cells that still work for recognition to interfere with their immune checkpoints. Cytotoxic T-lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are the most two characterized.

These molecular are self-tolerant under normal physiological contexts but easily powerless by malignancy [38,39]. Cancer cells aim to bind them with self-expressed specific receptors so that antitumor signalling and immune attack will be prevented. Then, sufficient tumor-associated antigen-presenting cells (APCs) and tumor infiltrating T cells will be extremely lacking in TME [40,41]. Although the immune defence never gives up, at the end, it is going to be beyond the diagnosing and fighting abilities of natural immune packages thus failing to reverse the immune abnormality [42].

The immune system and oncogenesis are both intricate biological machineries. The exact analysis of highly heterogeneous tumor immune microenvironment (TME) is fundamental to design the drug and scaffold combined biomaterials. Since the changes of TME are reflected mainly in both cancer cells and immune cells, immunomodulation is therefore multifaceted [35]. To come up with a working immunotherapeutic regimen, the following matters in tumor immunology should be taken into account: (a) poor immunogenicity of tumors, (b) serious immunosuppression towards immunocytes, (c) adequate priming, enough numbers and pinpoint phenotypes and antigen-specific actions of effective T cells [42]. In the past decades, significant advancements have been made in cancer immunotherapies, with cancer vaccines, immune checkpoint blockade (ICB) and ACT as representatives. Since increasing the number or quality of antineoplastic effector T cells in TME alone does not positively correlate with therapeutic outcomes, the fruitful advancements of cancer immunotherapy should also lie in programming immune cells in peripheral tissues or draining lymph nodes (dLNs) and modulating both immune cells and malignant cells in the TME [43].

Some exciting clinical results seemingly imply that treatment is getting closer to cure, yet far from people’s expectations, cancer immunotherapies cease to go forward due to a few obstructions. To get over these barriers and optimize the curative efficacy, biomaterial-based immunotherapeutic platforms as the interface between biomedical material engineering and immunopathology should be thought highly of [44,45]. Based on the profound understanding of different causes, changes, phases of cancers and different immunity, physical and mental conditions of patients, a comprehensive biomaterial treating systems can be eventually determined.

2.2. Significance and functions of 3D macroscale biomaterials

Biomaterial-derived strategies have been developed into highly customization which empower precise localized distribution, focused dosage concentration, optimized release kinetics of payloads and prolonged administrating periods. Among them, 3D macroscale biomaterials have gained an amenable momentum as one of the most crucial classes superior to other biomaterials [32,46]. The junction of biocompatible macro-materials and cancer immunotherapy is unique and inevitable that may allow for more reliable preclinical outcomes and more effective treatment care [47].

One of the aspects making these 3D macroscale biomaterials stand out needs to be with specialized emphasis on localized anchored adjuvant delivery. Despite a few achievements of preferred soluble injections in many pathological conditions, deficiencies of this administration method to cancer immunotherapies yet emerge. Firstly, off-target effects and rapid renal and hepatic clearance easily occur and therefore the high dosages or frequent doses of soluble therapeutics are necessitated, which often in all probability accumulate systemic toxicities and meanwhile lose patient compliance [48]. Additionally, it is difficult for some immune formulations such as soluble prophylactic vaccines to trigger strong enough native/foreign antitumor immune responses for ideal cancer immunotherapy [49]. The tightly topical arrangement based on macro-biomaterials enables to mitigate some concerns of systemic administrations. Once target position is found out and accessible, the treatment modality of bulk biomaterials can be applied locally through injection or implantation in situ, and then closely responsible for regional tumor immunomodulation. It is also worth noting that they are associated with complementary local and systematic cancer immunotherapy as well. As we all know, more than 90% of cancer deaths stem from metastasis and relapse, so the ideal treating approach is not only to direct at TME in situ, but to activate the systematic immunity of the body more effectively [50]. Luckily, although local treatment, the “abscopal effect” from such biomaterials could also result in systemic antitumor immune safeguard that is well exemplified by effective prohibition of the tumor disseminated metastasis and distant ectopic recurrence after local immunotherapy [51]. On the one hand, the encapsulated therapeutic molecular or cellular agents would enter and transport within the systemic circulation to expand antitumor effects beyond the primary site; on the other hand, a great number of the effector T cells, or antibodies originated from the foremost immune response primed by macroscale delivery vehicles can also be automatically manipulated for systemic deployment.

Another outstanding feature refers to the advantages of their macro-sizes and microstructures. The scaffold structures of macroscale bulk materials upgrade the interaction between biomaterials and cells. They could prompt encapsulation of immune cells for further immunocyte functionalization which lays a solid foundation to build up in vitro 3D experimental models [52]. Compared to in vivo animal models and in vitro 2D models, 3D frameworks not only possess structurally and functionally physiological environment-mimic matrices but also permit hierarchical control of biological processes in multidimensions which is extremely required in the explanation of immunomodulatory molecular and cellular mechanisms [53–55]. Moreover, suitable scaffolds can serve as cell harbour or the entrepot for co-delivering other chemical agents and biologic factors to support engineered cell cultivation [45,56,57]. No matter scientific research or clinical trials, macroscale biomaterial-manufactured 3D models could be utilized for the exploration of immune dysfunction and function at various biological levels as well as spatiotemporal scales. In the sense, they could pioneer a new era for the design and development of cancer immunotherapies.
to better therapeutic stability, higher “effective” doses, and less side effects. Besides, local immunomodulatory scaffolds play an important role in establishment of in vitro 3D models flourishing the researching tools for cancer immunotherapies. And it also makes sense that in addition to the functionality as conscientious loading carriers, the active immunomodulatory capability of 3D macroscale biomaterials themselves deserves to be investigated [58].

3. Behaviours and interactions of 3D biomaterials in tumor immunomodulation-related biosystems

The properties of materials usually make a great impact on their practical applications. For example, poly (lactide-co-glycolide) (PLG)-derived polymeric scaffolds suffer from drawbacks of brittleness which might make them too fragile to be implanted onto tumor resection bed or solid tumor neighbourhood [59]. By contrast, the injectable routes can partially optimize the available implantable methods. However, injection based on the needle can be adopted only if the biomaterials at the state of liquid or gel which significantly limits the types of applied materials. For instance, the improved resorbable and soft alginate scaffolds still rely on invasive surgery for implantation [59]. When injection, the rheological properties such as gelation time might adjust the injectability of 3D hydrogels. And the mechanical characteristics like deformation degree might affect the location and distribution of the bulk materials. For example, the surgically inaccessible sites and volume-limited spaces are easy to result in dissatisfactory localization without suitable exogenous materials [59]. In the aspect of biological properties, the systematic adverse effects (e.g., infectious inflammation, foreign body reactions) must be taken into consideration after their persistent presence to normal tissues or organs [60–63]. For example, some published reports demonstrated the observation of pancreatic cell impairments caused by incorrect immune attack during the treatment of alginate-based pancreatic tumor therapies [64].

A comprehensive evaluation of the behaviours and interactions and a thorough explanation of the processes and mechanisms within the material-immune system followed by establishing a bridge between these two systems seem overwhelming. Nevertheless, the feasible design and desirable optionality for materials-based immunotherapeutic strategies have been developed still at the outset stage and immunotherapeutic property-activity relationship-related literatures are that rare. Therefore, this part will try to explore the underlying property-function relationships when 3D macroscale biomaterials applied in the cancer immunotherapy particularly from the view of materials science and engineering (Fig. 3).

3.1. Physicochemical properties influencing the immunotherapeutic behaviours

Implantation and injection are the two of the most widespread-applied ways in 3D macroscale biomaterial-based immunotherapy. Implantable and injectable scaffolds or gels have some common regulatable physicochemical properties, mainly containing hydrophilicity, electric charge, mechanical strength, thermal stability, biodegradation rate, and controlled payload release which can be adjusted by the types, quantity, ratios and modification of the components or the fabrication techniques [65,66]. Alternatively, in terms of injectable soft gel-like biomaterials for higher spatiotemporal precision, other features namely injectability (e.g., a shear-thinning ability/a high compression strain), gelation duration and swelling ratio should also be regarded [51].

The accurate operation of physicochemical properties of materials is of utmost significance. The electrostatic interaction (positively/negatively charged) and hydrophobic effect (hydrophilicity/hydrophobicity) quite affect the loading efficiency of immunotherapeutic agents. Thus, the coordination among the pharmaceuticals and materials will elevate the potent encapsulation in defined doses. The implantable hydrogels in the form of tablets or pills are likely to be confronted with the brittle problems [67]. Therefore, the appropriate moulding mechanism needs to be determined in specific cases. For example, the physically crosslinked hydrogels usually exhibit lower mechanical strength than the chemically crosslinked hydrogels [51]. As for the controlled payload release, it is supposed to have some intrinsic connection with biodegradation rate of biomaterials which can be fundamentally ascribed to materials design. As tools to direct the immune reactions, 3D biomaterial scaffolds can be engineered with the physicochemical properties to augment the immune responses temporally and spatially [36]. Indeed, many experts have made many contributions to illuminating how the physicochemical properties influence the immunotherapeutic behaviours in order to motivate a potent immune response to defeat most of the immune-susceptible diseases especially cancers.

Injectable hydrogels require applicable gelling characteristics, related to the thermodynamic and rheological properties of 3D biomaterials. Thermo-responsiveness is one of the promising candidates whose gel windows should cover the physiological temperature. Many

![Fig. 3. Properties and interactions of 3D macroscale biomaterials influencing the tumor immunomodulation efficiency.](image-url)
synthetic polymers can be easily endowed with that. Take an example, Kyle Brewer et al. synthesized an array of thermo-responsive copolymers from poly (caprolactone) (PCL), poly (ethylene glycol) (PEG) and poly (propylene glycol) (PPG) by varying the proportion of PEG/PPG for cell therapies [68]. The percentage of PEG/PPG in the copolymers could change the specific phase transition temperature of copolymers. When the products with PEG:PPG in ratio of 1:2, they enabled to accomplish sol-gel transition at 28 °C and gelatinize when body temperature (37 °C) adequate for in vivo applications. CD4+ T-cells could be encapsulated in that copolymer-gelatinized 3D scaffolds. After injected to the target site, effector T-cells will be controllably released after lipase-based enzymatical degradation which makes the copolymers as potential delivery carriers for ACT.

In comparison, natural biomaterials are more suitable as easily degradation-regulatable implantable scaffolds. Long Ren et al. constructed macroporous scaffolds by combining two different components, stable methacrylate-modified hyaluronic acid (HA-MA) and readily hydrolysed derivatives methacrylate-modified oxidized hyaluronic acid (oxHA-MA) [69]. The in vivo degradation rate can be varied from 10 to 28 days via adjusting the blending ratios of HA-MA/oxHA-MA. Different antitumor agents including paclitaxel (PTX), R837 agonists, aCTLA-4 and anti-OX40 monoclonal antibody (mAb) were selected for combined cancer immunotherapy towards 4T1 breast cancer. Each of them could achieve spatiotemporal controlled release, therefore, the conversion of immunosuppressive TME in 4T1 breast cancer can be segmented and long-term. Hathaihanok Phuengkham et al. fabricated a cross-linked collagen-HA scaffold with both resiquimod and doxorubicin (DOX) loaded [70]. The degradability of the matrix can be modulated directly by the w/w ratio of collagen to HA. Under the condition that the w/w ratio of collagen to HA is 5:5, the matrix degradation sustained longest over four weeks, most advantageous for long-acting immunoregulation (Fig. 4. A-F). To facilitate higher accurate and intelligent control, Sangeetha Srinivasan et al. used auxiliary mathematical modelling to conduct temporal release of one or more immunomodulators [71]. The porous agarose scaffold with immunomodulator-loaded gelatin microparticles was generated from the empirical mathematical model based on the Weibull function and the Bayesian approach. The release profile data of specific molecules could be mimicked and modified in advance. This smart scaffold design strategy will sufficiently improve the materials properties and instructionally enhance the generation of endogenous regulatory dendritic cells (DCs) phenotype in vivo.

As the upgradation of single component 3D scaffolds, the incorporation of new components or multi-strand network usually improve the mechanical properties of 3D macroscopic substrates and it might award more intelligence to the biomaterials for morphological changes or performance activation to external stimuli [72]. For example, Sandeep T. Koshy et al. designed a series of nanocomposite alginate cryogels for protein drug delivery [73]. In the study, the entrapped Laponite nanoplatelets could slow the release of immune-related proteins with various sizes; charge, and functions because of electrostatic interaction whilst the electrostatic interaction between Laponite and alginate would result in the embrittlement of cryogels. Higher concentrations of Laponite attracted much stronger interaction varying the crosslinking and swelling levels inside the hydrogels so that the brittle gels will irreversibly deformable and fragmented hardly to be injected. Therefore, a moderate content of Laponite nanoplatelets in the system should be found to balance the slow release of protein drugs and feasible injectability of cryogels.

### 3.2. Cellular interactions supporting the immunotherapeutic functions

The size advantages of 3D macroscopic biomaterials open more opportunities for immunotherapies targeting to the cell level. The cyto-compatibility of these materials are basic for successful cellular adherence and survival. Natural or synthetic, organic or inorganic, newly-developed or long-studied biomaterials themselves are likely to accompany with acute inflammatory responses or even chronic foreign body reactions increasing the risk of systemic toxicity [74]. Post-processing like surficial modification might improve the biocompatibility of 3D scaffolds [75,76]. However, it is still questionable whether their degradation by-products would cause these adverse reactions in a long time. Then, a steady and safe space sponsored by inner tapering of endogenous regulatory dendritic cells (DCs) phenotype and long-term. Hathaichanok Phuengkham et al. fabricated a cross-linked collagen-HA scaffold with both resiquimod and doxorubicin (DOX) loaded [70]. The degradability of the matrix can be modulated directly by the w/w ratio of collagen to HA. Under the condition that the w/w ratio of collagen to HA is 5:5, the matrix degradation sustained longest over four weeks, most advantageous for long-acting immunoregulation (Fig. 4. A-F). To facilitate higher accurate and intelligent control, Sangeetha Srinivasan et al. used auxiliary mathematical modelling to conduct temporal release of one or more immunomodulators [71]. The porous agarose scaffold with immunomodulator-loaded gelatin microparticles was generated from the empirical mathematical model based on the Weibull function and the Bayesian approach. The release profile data of specific molecules could be mimicked and modified in advance. This smart scaffold design strategy will sufficiently improve the materials properties and instructionally enhance the generation of endogenous regulatory dendritic cells (DCs) phenotype in vivo.

As the upgradation of single component 3D scaffolds, the incorporation of new components or multi-strand network usually improve the mechanical properties of 3D macroscopic substrates and it might award more intelligence to the biomaterials for morphological changes or performance activation to external stimuli [72]. For example, Sandeep T. Koshy et al. designed a series of nanocomposite alginate cryogels for protein drug delivery [73]. In the study, the entrapped Laponite nanoplatelets could slow the release of immune-related proteins with various sizes; charge, and functions because of electrostatic interaction whilst the electrostatic interaction between Laponite and alginate would result in the embrittlement of cryogels. Higher concentrations of Laponite attracted much stronger interaction varying the crosslinking and swelling levels inside the hydrogels so that the brittle gels will irreversibly deformable and fragmented hardly to be injected. Therefore, a moderate content of Laponite nanoplatelets in the system should be found to balance the slow release of protein drugs and feasible injectability of cryogels.

### 3.2. Cellular interactions supporting the immunotherapeutic functions

The size advantages of 3D macroscopic biomaterials open more opportunities for immunotherapies targeting to the cell level. The cyto-compatibility of these materials are basic for successful cellular adherence and survival. Natural or synthetic, organic or inorganic, newly-developed or long-studied biomaterials themselves are likely to accompany with acute inflammatory responses or even chronic foreign body reactions increasing the risk of systemic toxicity [74]. Post-processing like surficial modification might improve the biocompatibility of 3D scaffolds [75,76]. However, it is still questionable whether their degradation by-products would cause these adverse reactions in a long time. Then, a steady and safe space sponsored by inner

---

**Fig. 4.** Physicochemical properties and cellular interactions influencing the immunotherapeutic efficiency. (A) The scaffold co-delivering iNCVs (R848), DOX, and ICB molecules (aPD-L1/aPD-1) to induce an immunogenic tumor phenotype. (B) SEM analysis of the morphology and (C) pore size of collagen/HA scaffolds prepared in an enzyme-containing buffer (pH 7.4 or 6.5). Reproduced with permission from Ref. [70]. Copyright 2019 WILEY-VCH Verlag GmbH & Co. KGaA. (D) Different mechanical factors in cell-material/cell-cell interactions regulating immune cell morphologies, behaviours, and functions. Reproduced with permission from Ref. [92]. Copyright 2020 Elsevier.
microstructure is of necessity for cellular growth, proliferation, and migration. Generally, there usually exist enough porous structures in cryogels and some inorganic scaffolds suitable for cell migration and accommodation, but less porous hydrogels can realize cell encapsulation and attachment and co-delivery with immunomodulatory agents [77–79]. Besides, the inner properties like hydrophilicity, electric charge, ionic strength could also affect the habits of immune cells. The hydrophilic and positive-charged surfaces are relatively apt to cellular contact, but excessively positive charges are bound to be lethal for immunocytes [80]. More importantly, during immunotherapy, the polarization of immune cells into competent phenotype for effective immune responses is vital. The immunologically inert 3D biomaterials could also have the potential capability to induce the T cell functionalization or macrophage polarization [81]. On this occasion, various effects on generating subtle and intricate interactions between materials and immune cells should be further recognized.

Koyal Garg et al. studied the functional polarization of macrophages in response to distinct fiber diameter and pore size of electrospun scaffolds [82]. The research firstly indicated that the pore size of a scaffold was a more decisive in the macrophage polarization compared to the fiber diameter. The thinner fibrous scaffolds yielded from lower polydioxanone (PDO) concentrations intend to have smaller pore sizes and porosity which is likely to induce the M1 type of macrophages. In immunosuppressive TME, the transition of tumor associated immunocytes [80]. More importantly, during immunotherapy, the polarization of immune cells into competent phenotype for effective immune responses is vital. The immunologically inert 3D biomaterials could also have the potential capability to induce the T cell functionalization or macrophage polarization [81]. On this occasion, various effects on generating subtle and intricate interactions between materials and immune cells should be further recognized.

Table 1

| Advantages                                                                 | Potential micro needles                                      |
|---------------------------------------------------------------------------|-------------------------------------------------------------|
| Provide physical structures for immunoregulators/cells                   | Suitable gelation period and properties                      |
| In situ immunocytes activation                                            | Require large gauge needle                                  |
| Controlled release profiles                                              | Simple to apply                                             |
|                                                                           | Minimally invasive                                          |
|                                                                           | High patient compliance                                     |
|                                                                           | Sustained release                                           |
|                                                                           | Low required doses                                          |

3.3. Others

The self-assembly capability of some biomacromolecule-derived materials (typically nucleic acids and peptides) facilitates endeavours to spontaneously organize into the 3D scaffolds with rational and variable microstructures and disorganize for therapeutic release upon external stimulus.

The base complementary pairing guarantees precise and efficient self-assembly of DNA. The varied and adjustable DNA sequences lead to the strict and controllable structures. Tomoya Yata et al. reported a sort of composite gold nanoparticle (Au NP)-DNA hydrogels for immunostimulatory tumor photothermal immunotherapy [94]. The DNA hydrogels were composed of hexapod-like structured DNA (hexapodna) with CpG sequences and Au nanospheres or nanorods (Au NSs/Au NRs). The formation of structure-specific Au NP-DNA hydrogels resulted from complementary pairing bases of designed hexapodna and directional oligonucleotide (ODN)-modified Au NPs. These well-ordered Au NP-DNA hydrogels displayed the release of immunostimulatory hexapodna under laser irradiation. The inner connection manners made a difference on the thermal stability of the combination of hexapodna and directionol oligonucleotide (ODN)-modified Au NPs which varied the efficiency of immunotherapeutic disruption behaviour.

The peptide hydrogels are another one of the common self-assembly hydrogels. Due to the variety and number of amino acids in peptide, these hydrogels are not only of many classes, but also have excellent designability in structure and performance. Since each amino acid have own hydrophilicity/hydrophobicity, positively/negatively charge and chemical groups in side chains, it was acknowledged that a lot of mutual effects, more than hydrophobic forces, electrostatic interaction, hydrogen-bonding, and ionic reinforcement, could master the gelatinization and denature destinies of self-assembled peptide hydrogels [95]. A good command of structure-activity correlation in peptide hydrogels will also benefit materials design on demand.

Otherwise, some factors like drug formulation, injection technique and delivery mode could also influence the treating efficacy of cancer immunotherapy (Table 1) [96]. For example, in the study of Jianghua
Wang et al., CpG-modified nanovaccines (CNVs) were designed into three different delivery modes: mono-pulse staggered-pulse, and gel-confined. The former two nano vaccinations passively drain to LNs due to their size; in the inverse scenario, gel-confined CNVs were actively delivered to LNs. After entering the dLNs, these three CNVs exhibited three different spatiotemporal distribution and utilization. The interaction of DCs with T cells were subsequently changed, leading to individualized T cell-mediated antitumor immune response [97].

The properties of engineered materials that can edit cancer immuno-biology and the responses of immune system exerted by specific interventions are numerous. A better understanding of material-immune system interactions will clarify the underlying interface modes between these two counterparts which is constructive for affording a set of biomaterials design criteria for effective immunotherapies. Indeed, the development of such an integrated guideline is exceptionally elementary so that more energies need to be devoted to learning the property-function relationships. This will enable prevalent applications of immunotherapeutic 3D macroscale biomaterial strategies for more intractable cancers.

4. Modern immunotherapeutic strategies based on 3D macroscale biomaterials

The 3D macroscale biomaterial immunotherapeutic platforms are multitudinous that can be classified according to their components, preparation methods, administration routes or immunomodulation principles. They are generally constituted of natural components or synthetic polymers (e.g., collagen, alginites, HA; PEG, PLGA, mesoporous silica, etc.). The 3D macroscale constructs can be established by in vitro simple crosslinking, in vivo rapid sol-gel phase transition, in situ chemically polymerized assembly or advanced 3D printing and self-assembly techniques, etc [98]. With tumor antigens and adjuvants, immunostimulatory or immunosuppressive molecules, and even bioactive immune cells embraced in, these 3D scaffolds or hydrogels become immunostimulatory or immunosuppressive molecules, and even bioactive immune cells to achieve immunomodulation. As macroscale delivery systems, 3D scaffolds can be further loaded with other chemotherapeutic drugs and photo-/sono-/thermo-/magneto-sensitizers to mediate combinational immunotherapeutic strategies. Higher spatiotemporal controllability, immune reaction, and therapeutic efficacy will be obtained due to the attendance of 3D macroscale biomaterials [5,99,100]. In addition, since 3D in vitro models are considerable in scientific research, 3D macroscale scaffolds have been considered to develop as biomimetic organoids, in which dynamic biological and therapeutic processes can be evaluated simultaneously [101]. Each immunotherapy regimen would present its own virtues when executed appropriately in particular cases. In this section, the modern immunotherapeutic strategies based on 3D macroscale biomaterials will be categorized and discussed according to the objects exercising immunomodulatory functions and some remarkable immunotherapeutic paradigms will be enumerated (Fig. 5).

4.1. Delivery of immunomodulatory agents by 3D macroscale platforms

The 3D macroscale platforms have been widely investigated as drug delivery systems [102,103]. Different kinds of immunomodulatory agents could be simply incorporated into them via gentle procedures. Small immunotherapeutic drugs, such as pathway modulators, can be encapsulated in quantities, locally applied, and durably released. For example, interleukin (IL). It is short half-life in vivo and high doses-dependent toxicity to normal organs. The localized single long-term administration by 3D therapeutic biomaterials enhances efficacy and lessens side effects which makes 3D scaffolds outperform conventional systematic delivery of IL [104]. For macromolecular immunomodulatory drugs, such as antigens and antibodies, 3D macroscale platforms can help to sustain their special biological activity and increase their bioavailability in physiological circumstances [105]. For example, protein or nucleic acid-derived antigens and immune adjuvants. They are fragile to experience inactivation and denaturation during circulation. Hence, prolonging their lifespan by 3D macroscale biomaterials will ensure them work as effective cancer vaccines [36,106]. 3D scaffold materials also extend delivery business to cellular level promoting ACT therapy. The immune cells can combine with immunomodulatory molecules, concentrated and carried by 3D macroscale vehicles for synergistic therapies. Therefore, sufficient modulation of

---

**Fig. 5.** Some classical immunotherapeutic strategies based on 3D macroscale biomaterial platforms. 3D macroscale biomaterials can load and deliver bioactive molecules as well as immune-related cells to achieve immunotherapy in tumor sites. They can also be further loaded with other cancer therapeutic agents for more efficient cancer combination therapy. In addition to supporting 3D structures as a carrier platform, part of the 3D bioscaffolds themselves can play a significant immunomodulatory role to treat tumors without any loading or further modification.
immune performances will be provoked in this localizable way [107] (Fig. 6).

There are many successful design of 3D scaffold-based cancer vaccines and immune checkpoint blocking. For instance, Bin Zheng et al. prepared an injectable hydrogel vaccine from PLGA-PEG-PLGA [108]. NIR-triggered antigens and non-pathogenic Sendai virus adjuvants could recruit and stimulate DCs, boost antigen presentation, activate anticancer immunity and induce immune memory. Yimou Gong et al. fabricated injectable reactive oxygen species (ROS)-responsive covalently crosslinked hydrogels [109]. The hydrogels can intelligently release αPD-L1 antibodies blocking suppressive immune recognition of B16F10 melanoma cells. Most recently, in the research of Chun Gwon Park et al. the crucial role of hydrogel in its mediated immunoregulatory strategy has been highlighted and further revealed [110]. The 3D hydrogels made from thiol-modified HA and poly (ethylene glycol) diacylate (PEGDA) were used to load antibodies (αCTLA-4, αPD-1), cytokines (IL-15sa), or small molecules [lenalidomide, celecoxib, 2′3′-c-di-AM(PS)2 (Rp,Rp) (“STING-RR”), R848] and implanted into the tumor resection site. The extended release and immunotherapeutic effects of several different payloads have been studied for perioperative immunotherapy. Although extended regional release of these agents was realized in the adjacent to tumors, the most durable perioperative immune response presented when administering the agonists of innate immunity-loaded hydrogels (STING-RR and R848) which accounted for converting an immunosuppressive post-resection TME into an immunostimulatory type. Next, the researchers managed to confirm that these

![Fig. 6. 3D macroscale platforms for immunomodulatory molecules and cells delivery. (A) The in situ sprayed bioresponsive fibrin gel containing αCD47@CaCO3 NPs within the post-surgery tumor bed, promoting both polarization of TAM to an M1-like phenotype and blockade of the ‘don’t eat me’ signal in cancer cells. Reproduced with permission from Ref. [114]. Copyright 2018 The Author(s), under exclusive licence to Springer Nature Limited. (B) The microneedle-based transcutaneous platform loaded with self-assembled m-HA NPs for encapsulation and release of immunotherapeutic indoleamine 2,3-dioxygenase (IDO) inhibitor 1-MT and αPD-1. Reproduced with permission from Ref. [115]. Copyright 2016 American Chemical Society. (C) The fabrication of OVA@R837-PLGA NPs for immune stimulation as a nanovaccine and ultrasound-triggered release of NPs from the self-healing nanocomposite gel. Reproduced with permission from Ref. [116]. Copyright 2021 American Chemical Society. (D) Subcutaneous injection of chemokine-attracting DCs loaded in mesoporous silica microrods mixed with DNA-encoding tumor antigen polyplexes resulting in the formation of a 3D macroporous scaffold. Reproduced with permission from Ref. [117]. Copyright 2020 American Chemical Society. (E) A porous scaffold with oxygen reservoirs enhancing CAR-T cell immunotherapy of solid tumors by intratumoral injection. Reproduced with permission from Ref. [118]. Copyright 2020 American Chemical Society. (F) The formation and immune action mechanism of a peptide nanofibrous hydrogel self-assembled with tumor antigens, αPD-1 antibodies and exogenous DCs. Reproduced with permission from Ref. [119]. Copyright 2018 American Chemical Society.]

---

S. Han and J. Wu

Bioactive Materials 17 (2022) 300–319
agonists of innate immunity were effective only when released locally from the hydrogel. By contrasting the groups of blank controls, empty hydrogel controls, R848-loaded hydrogels, weekly intravenous injection (free R848), weekly intraperitoneal injection (free R848), and local delivery of R848 solution (single dose), the facts indicated that perioperative delivery of R848 from hydrogels conferred more survival benefit in most mice. The immunotherapeutic efficacy was also substantiated in spontaneous lung metastasis models. All these experimental results have demonstrated the outstanding functions of the engineered hydrogel strategies for cancer immunotherapy which could not only prevent recurrence but also avoid metastases of residual tumor tissues.

The porous and hydrophilic 3D networks of macroscale biomaterials are promising for cellular therapeutics. Afeng Yang et al. designed α-cyclodextrin and PEG co-crosslinked hydrogels for DC cancer vaccines [111]. The co-laden DOX/CpG nanoparticles as prodrugs offered DOX-stimulated tumor antigens and immunoadjuvants rising the antigen presentation levels of DCs. The implantation of exogenous DCs was compensatory to the insufficiency of endogenous DCs. Therefore, this 3D biomaterial-mediated cell vaccine could remarkably maximize T cell infiltration and killing to reverse intratumoral immune insensitivity. ACT is another hopeful strategy in cancer immunotherapy, yet its immune reactions are always limited by several major constraints, including high costs but low rates of ex vivo cell “training”, poor functionality, and fragile vitality of transplanted cell products [112]. The interaction between immunocytes and macroscale scaffolds will be advantageous for cell encapsulation, viability or orientational differentiation. Sirkka B Stephan et al. successfully fabricated a kind of new hydrogels by alginate with collagen-mimetic peptide FPGOFGER which could carry T cells and implant in situ for adaptive T-cell transfer [113]. In both 4T1 mouse breast tumor resection model and advanced-stage inoperable tumor models, scaffold-delivered lymphocytes could maximize the immune interventions halting cancer aggravation. By comparing the groups treating with intravenous injection, intracavitory injection (with or without superagonist/antibody prestimulation), and scaffold delivery, respectively, using the same dose of T cells, the scaffold delivery did produce more antigenic effectiveness than that of conventional injection. Further cell trace found that intravenously injected lymphocytes tended to accumulate in the spleen and the liver, while peritumourally injected T cells tended to rapidly exhaust functions, both ineffective for ACT. Differentially, the scaffold-supported T cells could deal with those above problems and offer the possibility for high-speed and high-yield cell proliferation.

As far, codelivery of over one single therapeutic agent in an appropriately defined pattern has become the mainstream trend in cancer immunotherapy. 3D macroscale materials can accomplish this task. Therein, multiple therapeutics would strike synergistic or additive effects overcoming the limitations of one component and improving overall therapeutic efficacy [120]. Yingge Shi et al. developed an injectable polypeptide hydrogel depot with both DOX and aPD-L1 delivered [121]. DOX elicits immunogenic cell death (ICD) to produce immune effects and CpG arousing synergistic immune stimulation, the pramolecular hydrogel vaccine (DSHV) system with a T-helper cell epitope peptide antigen [152]. The well-built injectable hydrogels have formed to locally improve the stromal immunotherapeutic efficacy [120].

...hydrogels could arouse a long-term immune memory effect and further prevent postoperative metastases and recurrence.

With decades of hard efforts, several breakthroughs of 3D scaffold-based cancer immunotherapy have been achieved with exciting preclinical responses applied for immune checkpoint inhibition, cancer vaccines, and chimeric antigen receptor T (CAR-T) cells transfer. Some representatives of recently reported choreographed 3D macroscale biomaterial depts for delivery of immunomodulatory agents are summarized in Table 2.

P (Me-D-1MT)-PEG-P (Me-D-1MT): poly (l-methionine-dextro-1-methyl tryptophan)-poly (ethylene glycol)-poly (l-methionine-dextro-1-methyl tryptophan) triblock copolymer; Zeb: Zebularine; MA-alginate: methacrylated alginate; MA-PEG: methacrylated poly (ethylene glycol); GO: graphene oxide; PCL-PEG-PCL: poly (caprolactone)-poly (ethylene glycol)-poly (caprolactone); PDLLA-PEG-PDLLA: poly (D, l-lactide)-poly (ethylene glycol)-poly (D, l-lactide); ODEX: oxidized dextran; PECT: Poly (ε-caprolactone-co-1,4,8-trioxo [4,6]spiro-9-undecanone)-poly (ethylene glycol)-poly (ε-caprolactone-co-1,4,8-trioxo [4,6]spiro-9-undecanone); EAASCs: poly (ethylene glycol)-b-poly (2-amino ethyl methacrylate)-b-poly (2-(hexamethylene imine) ethyl methacrylate-co-2-(dibutyl amino) ethyl methacrylate); α-CD: α-cyclodextrin; MIT: mitoxantrone; Gel-PEG-Cys: thiolated gelatin poly (ethylene glycol); LPS: Lipopolysaccharide; IMQ: Imiquimod; CDNs: cyclic dinucleotide, dithio-(Rp,Rp)-[cyclic [A (2′-5′)pA (3′,5′)p] ]; BBN: N-Butyln-(4-hydroxybutyl) nitroamine.

4.2. Immunoregulatory effects sponsored by 3D macroscale matrices

The immune stimulation from 3D materials themselves navigates a novel direction for cancer immunotherapy. The scaffolds self-assembled by nucleic acids (viz. DNA and RNA) or peptides appear as a budding branch. Unlike common hydrogels/scaffolds made from polysaccharides and proteins, they are active in immunity by self-participation which might be applicable as cancer vaccines [146,147]. Such 3D biomaterials should not only provide a macroscale structure for immune agent delivery or immune cell expansion but act as a functional entity like cancer antigens or APCs to activate antitumor immunity [148–150]. They can be inserted to the available place by an easy or less invasive way. And if possible, these 3D biomaterials can move and spread to anywhere conformed to locally improve the stromal immunotherapeutic efficacy [151].

The DNAs represent the components that are both constructional and functional units. Yu Shao et al. put forward an unmethylated CpG sub-micromolecular hydrogel vaccine (DSHV) system with a T-helper cell epitope peptide antigen [152]. The well-built injectable hydrogels have rigid network and mimetic function as LNMs. By antigens triggering strong immune effects and CpG arousing synergistic immune stimulation, the APCs can be efficiently recruited and activated locally to induce high concentration of specific antibodies for constant recognition and defeat of target tumor cells (Fig. 7. A). Yuka Umeiki et al. additionally incorporated tumor antigens as well as immune cells into the self-assembling DNA hydrogels to boost antitumor immunity [153]. The biocompatible and immunostimulatory hydrogels did not affect the cell viability but efficiently activated the DCs and macrophages for antigen-specific responses. Lately, Jaiwoo Lee et al. improved the DNA hydrogels with more precise liberation and higher immunocyte filtration of therapeutic DNAs [154]. The novel PD-1 DNA polyamter hydrogels were engineered with Cas9/sgRNA editability from which the free PD-1 aptamer sequences can be released after designated cut. Afterwards, the tumor cell survival could be hugely threatened with the T cell activity exacerbating.

Alternatively, antigenic peptides are also available for co-assembled hydrogels. Huaimin Wang et al. tried to develop a co-assemble molecular hydrogel with peptide gelators and OVA protein introduced into [155]. The hydrogels formed by phosphatase catalysed were supposed to be efficient vaccine adjuvants for optimizing the humoral immune
Recently reported 3D macroscale biomaterial depots for delivery of immunomodulatory agents for cancer immunotherapy.

| Therapeutic strategies | Scaffold composition | Gelling/Assembly mechanisms | Immunomodulatory agents | Administration routes | Tumor models | Ref. |
|------------------------|----------------------|-----------------------------|-------------------------|-----------------------|--------------|------|
| **ICB**                |                      |                             |                         |                       |              |      |
| Fibrin                 |                      | Enzyme catalysis crosslinking (fibrinogen with thrombin) | aCD47/CaCO3 NPs        | Spray into the tumor resection cavity | C57BL/6 mice; B16F10 melanoma cells | [114] |
| HA modified with 1-methyl-DL-tryptophan (1-MT) |                      |                             | aPD-1                   | Transcutaneous administration | C57BL/6 mice; B16F10 melanoma cells | [115] |
| PVA                   |                      | Chemical conjugation (phenylboronic acid and the cis,1,3-diol in PVA) | aPD-1/CaCO3 NPs and Zeb | Peritumoral injection | C57BL/6 mice; B16F10 melanoma cells | [125] |
| P (Me-D-1MT)-PEG-P (Me-D-1MT) |                      | Thermo-responsive | aPD-L1                  | Intratumoral injection | C57BL/6 mice; B16F10 melanoma cells | [126] |
| **Vaccines**           |                      |                             |                         |                       |              |      |
| MA-alginate           |                      | Cryogelation technique and ionic crosslinking | CpG ODNs and GM-CSF    | Subcutaneous injection | BALB/cj mice; HER2-neu-overexpressing DD breast cancer cells | [127] |
| MA-alginate and MA-PEG |                      |                             |                         |                       |              |      |
| MA-alginate and RGD peptides |              |                             |                         |                       |              |      |
| HA                   |                      | Microneedle patch           | Whole tumor lysate (with melanin) and GM-CSF | Intradermal administration | C57BL/6 mice; B16F10 melanoma cells | [130] |
| GO and PEI            |                      | Electrostatic interaction   | mOVA (mRNA) and R848   | Subcutaneous injection | C57BL/6 mice; mycoplasma-free B16-OVA cells and lung metastasis | [131] |
| PCL-PEG-PCL           |                      | Thermo-responsive           | OVA NPs and GM-CSF     | Subcutaneous injection | C57BL/6 mice | [132] |
| PDLLA-PEG-PDLLA       |                      | Thermo-responsive           | CpG ODNs, GM-CSF and one or multiple antigens | Subcutaneous injection | C57BL/6 mice; MLL-AF9 AML cells | [128] |
| 8-arm-PEG and ODEX    |                      | Covalent crosslinking       | Tumor lysate protein antigens (OVA) and CpG@PEI | Subcutaneous injection | C57BL/6 mice; B16F10 melanoma cells | [129] |
| α-CD and PEG          |                      | Covalent crosslinking       | CpG/DOX modified B16 cells and DCs | Subcutaneous injection | C57BL/6 mice; B16 melanoma cells | [135] |
| Mesoporous silica microrods |              | Self-assembly               | pOVA@PEI polyplex (pDNA encoding tumor antigen) | Subcutaneous injection | C57BL/6 mice; mycoplasma-free B16-OVA cells | [137] |
| PECT NPs and EAASc NPs |                      | Self-assembly               | Curcumin; CpG ODN and peptide | In situ injection at the postoperative location | C57BL/6 mice; BALB/c mice | [136] |
| **ACT**               |                      |                             |                         |                       |              |      |
| HA/MA/cxHA-MA        |                      | Free radicals-based cryogelation | Human natural killer cells | Implantation in situ | BALB/c mice with incompletely resected MDA-MB-231 tumor | [137] |
| Alginate              |                      | Ionic crosslinking and cryogelation | Human activated T cells | In vitro static transduction of T Cells | NSG mice with lymphoma xenograft model using the FFLac-labelled CD19 human Daudi tumor cells | [138] |
| Polysiloxane-peptide (PIC) |              | Thermo-responsive           | Pre-activated T cells | Subcutaneous injection | C57BL/6 J mice | [139] |
| Decellularized lymph node |                      | Formic acid, acetic acid, or citric acid treatment | Dendritic cells | Subcutaneous injection | C57BL/6 mice with E.G7-OVA tumor | [140] |
| HEMOXCell (marine hemoglobin) and alginate microspheres on Teflon plates |              | Ionic crosslinking         | CAR T cells; IL-15 | Intratumoral injection | Combined immune deficiency NPG/Vst mice; SKOV-3 (GFP+)-cells | [118] |
| RADA16 peptides       |                      | Self-assembly               | DCs, aPD-1 and tumor antigens | Subcutaneous injection | C57BL/6 mice subcutaneously injected EG7-OVA lymphoma cells | [119] |
| Oligopeptide precursors |                      | Enzyme-assisted self-assembly | MIT and siIDO1 coloaded ZIF-8 nano-carriers; glioma-associated macrophage membrane | Intracavitary injection | GL261R132H-bearing mice with postoperative glioma | [141] |
| HA-MA                 |                      | Photo-crosslinking          | aPD-L1-conjugated platelets and CAR-T cells | Implantation | NOD-scid IL2rg-def (NSG) mice; WM115 human melanoma post-surgery | [142] |
| PEGDA/Gel-PEG-Cys     |                      | Photo-crosslinking          | M1 macrophages; LPS and IFN-γ | Subcutaneous injection | Athymic nude mice (BALB/c nu/nu) with subcutaneous MHCC97L xenograft | [143] |
| **Others**            |                      |                             |                         |                       |              |      |
| Pluronic F-127 N6-(1-iminoethyll)-L-lysine-Multidomain Peptides |              | Thermal-responsive           | IMQ/Liposomes | In situ injection | Mice with 4T1 breast cancer C57BL/6 mice with MOC1 oral tumor cells | [114] |

**Table 2**
reactions. The study also emphasized that the D-peptide hydrogel was more promising adjuvant activating immunity than the L-peptide while the exact mechanisms still needed to keep exploration. Xinxin Li et al. opted for another two potential stimulating peptides and combined them into new supramolecules (Nap-G\textsuperscript{D}F\textsuperscript{D}F\textsuperscript{D}YTKPR) which could self-assemble into either nanofiber scaffolds or hydrogels \cite{156}. The derivative instruments intended to govern antitumor CD8\textsuperscript{+} T immune responses by increasing macrophages phagocytosis, expediting DCs maturation, promoting antigen presentation and stimulating cytokines secretion.
The nucleic acids and peptides share a common characteristic that their constituent units (either bases or amino acids) are minimalistic, countable, and highly specific so that there have existed mature technologies to produce them in large-scale [157]. This will contribute to the applications of these 3D scaffolds as immunomodulatory matrices for clinical immunotherapy.

A minority of small molecules have also been used in the design of 3D scaffolds with only a few trials reported. Muchao Chen et al. selected steroid drugs to self-assemble carrier-free nanofiber hydrogels [158]. The anti-inflammatory betamethasone phosphate disodium (BetP) mixed with calcium ions could transform into gel for local delivery of aPD-L1 antibodies. As a functional immune-reprograming program, this system can not only reverse the immunosuppressive TME by the active scaffold, but also synergistically release aPD-L1 to stimulate the antitumor immune activity. Feihu Wang and coworkers successfully constructed drug-based supramolecular gelator for local ICB therapy [159]. In the system, amphiphilic prodrug, diCPT-PLGLAG-IRGD were synthesized by two camptothecin (CPT) petals and hydrophilic IRGD parts conjugated with a both redox and matrix metalloproteinase 2 (MMP-2) responsive linker (PLGLAG peptide). This prodrug gelator could first spontaneously assemble into supramolecular nanotubes and then gelatinize via quick sol-gel transition. The small-molecule prodrugs with unique structures acted as both chemotherapeutic and aPD-1 carrier for responsive combination chemotherapy.

The in vivo results revealed that this versatile carrier induced complete regression of GL-261 brain tumors and robust and durable systemic immunity inhibiting cancer recurrence and metastasis. Similarly, these researchers continued to use the diCPT-IRGD backbones and electrostatically complexed with STING agonists (c-di-AMP, CDA) for self-assembly as a local reservoir [160]. The hydrogels resulted in the extended release of CDA immunomodulators and CPT chemo-drugs to awaken both the innate and adaptive antitumor immunity (Fig. 7. B).

For “inert” biomaterials (3D delivery vehicles without immunomodulatory effects themselves), with the post-conjugation or modification, they can be allowed to function like biomimetic extracellular matrixes (ECM), as immune regulators rather than mere delivery tools. It is of practical significance especially in cellular immunotherapy. A biomimetic synthetic APCs matrix for T lymphocytes stimulation is by far one of the most feasible approaches for cancer immunotherapeutic applications. The ideal microenvironments should exhibit pores with diameter of 50–500 μm for cell migration and cell activity maintaining [161]. After specific antigen decorated onto the ECM-like 3D scaffolds, signal ligand-mediated communication will enable cell differentiation and expansion improving the functionality and quantity of antigen-specific T cells [162]. The therapeutic T-cell ex vivo expansion of high quality is one of the most vital portions in ACT. The group of David J. Mooney have described an inorganic system and summarized into a detailed protocol [163,164]. The system was comprised of degradable mesoporous silica microrods coated with liposomes-formed lipid bilayer which can be assembled into a bracket with a spatial structure by interacting with T cells. The fluid lipid bilayer can be inert with membrane-bound ligands (e.g., antibodies, cytokines) for T cell activation and the mesoporous silica enable sustained release of soluble paracrine cues like mitogenic factors. Compared to some conventional methods or commercial products, the scaffold facilitates ex vivo cell manipulation of ACT in low cost, rapid speed, and high efficiency, which can be assembled in approximately 4 h for several-fold greater expansion or faster enrichment of rare T-cells clones within 2–4 weeks.

In stead of abovementioned artificial formulations which usually requires high cost or multiple synthetic steps, Qin Fan et al. innovatively took advantage of coagulation or clotting, a natural process, to get a gel-like material [165]. The novel blood clot 3D scaffold can be formed using autologous blood, reducing adverse immunogenicity. In the blood clot scaffold, the main components are hydrated fibrous network and trapped red blood cells (RBCs). It makes the blood clot an ideal immune niche. RBCs in different states such as oxidized, damaged, or senescent periods, can implement important immune modulation in the innate immune system, including promoting DC maturity, macrophage polarization and T cells proliferation, which deserve to be considered as potential cancer vaccines (Fig. 7. C). Furthermore, in company with tumor-associated antigen and adjuvant plus ICB, it has been confirmed that the blood clot vaccine could elicit an effective anticancer immune response in both B16F10 and 4T1 tumor models. It is a very interesting idea, harnessing human’s own natural physiological processes for immunotherapy, that will light a new orientation of immunotherapeutic matrices.

4.3. Multifunctional 3D macroscale biomaterials for combined immunotherapy

The unsatisfactory immunotherapeutic outcomes in clinics usually come from weak and short-lasting anti-tumor immunity. The combination of multiple tumor therapies is expected to significantly improve the intensity and period of tumor immunotherapy. 3D macroscale scaffolds have strong competence to store different cancer therapeutics. Therefore, 3D biomaterial-assisted cancer immune treatments can undergo the cooperation from chemotherapy, radiotherapy, photothermal or photodynamic therapy and other therapeutic techniques. It will promise enhanced and prolonged immune responses to fortify the caner therapeutic efficiency [166].

Chemotherapy-induced cell death is one of the most common ways to increase tumor immunogenicity. Many studies have shown that chemotherapeutic agents do not entirely depend on their cytotoxicity to kill tumors. Some chemotherapeutic drugs also induce ICD, during which apoptotic cells release immune-related signals to initiate tumor-specific immune responses [167,168]. Synthetic polymeric scaffolds with prominent physiochemical performances have been developed for immunochemistry, lots of which have thermosensitive injectability and stimuli-responsive drug delivery [74,169,170]. Qiang Lv et al. developed trilob-copolymer hydrogels from poly (ε-caprolactone)-glutamate)-poly (ethylene glycol)-poly (ε-caprolactone) (PEG-PEL) for local treatment of melanoma [171]. DOX, IL-2 and IFN-γ were encapsulated in this chemoimmunotherapeutic system which could not only accelerate cell apoptosis but improve population of CD3+CD4+ and CD3+CD8+ T cells. Lei Jiang et al. also designed a thermostensitive injectable hydrogel based on PLGA-PEG-PLA trilob copolymers as a delivery matrix [172]. The incorporated NPs can be controllably released for sustained tumor regression which carried the anticancer drugs DOX inside and made their outer arginine-rich molecules as inducible nitric oxide synthase (iNOS) substrate polarizing macrophages to M1 type. And Farrukh Vohidov et al. selected poly lactic acid (PLA), PEG, and poly (N-isopropylacrylamide) (PNIPAM) as tri-block to synthesize bottlebrush copolymer-based injectable hydrogels. After intratumoral rapid formation of the hydrogels, both PTX and toll-like receptor (TLR) 7/8 agonist resiquimod could be delivered to the tumor in situ [173]. Based on the cancer immunochemistry, CT26-bearing mice suffered from enhanced therapeutic effects compared to the administration with each drug alone. Chao Wang et al. engineered an in situ-forming and TME ROS-degradable PVA scaffold, allowing the local delivery of gemcitabine (GEM) and aPD-L1 antibody in a programmed fashion [174]. This bioresponsive aPD-L1/GEM scaffolds promised combined chemoimmunochemistry with GEM promoting immunogenic tumor phenotype and ICB prohibiting PD-1/PD-L1 pathway for immune-mediated tumor destruction.

Many biocompatible naturally occurring biomacromolecule are used to construct 3D scaffolds, mostly to treat poorly immunogenic TME for immunochemotherapy [175-177] (Fig. 8. A). Kosuke Ueda et al. investigated the synergistic anticancer effects of sorafenib and IFN-α with HA-tyramine (HA-Tyr) hydrogels as delivery platforms in human RCC-xenografted nude mice [178]. The HA-Tyr hydrogels addressed some problems including immune tolerability and dose limitation in the IFN-α therapy for metastatic renal cell carcinoma. Hathaichanok
Phuengkham et al. reported a multifunctional implantable scaffold made of collagen and HA which was designed to bring synergistic immunomodulatory actions to postoperative tumor resection bed [179]. In this system, GEM served as a myeloid-derived suppressor cell (MDSC)-depleting agent rising the immunogenicity in TME and cancer vaccines comprising whole tumor lysates-based antigens and poly (I:C) loaded nanogels-based adjuvants could elicit tumor-specific immune attack. This immune niche showed desirable treating efficacy even for the advanced stage 4T1 breast tumors. Another injectable alginate cryogels were prepared by Tomás Bauleth-Ramos et al. [180]. The cryogels could be loaded with GM-CSF, CpG ODNs, and ICD-induced p53 activator Nutlin-3a (Nut-3a) in the package of spermine-modified acetalated dextran NPs (Sp-AcDEX NPs). The antitumor immune responses will be initiated by the specific T-cell activation. Recently, Yu Chao et al. developed a kind of localized cocktail chemoimmunotherapy for robust immune trigger [181]. The injectable alginate could undergo gelation in the presence of Ca$^{2+}$ in TME. A series of chemotherapeutic drugs (DOX or OXA), immune adjuvants (R837), and immune checkpoint inhibitors (aPD-L1) in the alginate excipients could be released in a sustained way to further amplify the antitumor immunity. This therapeutic cocktail formulations optimized current therapeutics and the authors claimed that it would be hopefully pushed into clinical trials in nearly 3 years. Furthermore, Hongjuan Zhao et al. developed an implantable drug-built scaffold with bioresponsive nanoarrays [182]. DOX as chemotherapeutics and JQ1 as epigenetic modulators were loaded into HA-modified polydopamine NPs. Another part of free JQ1 mixed with NPs conjugated with ROS-responsive linker molecules to fabricate immunotherapeutic nanoarray. It was confirmed that this strategy could change “cold tumors” into “hot tumors” and facilitate systemic immunogenicity inhibiting potential tumor recurrence or metastasis post surgery.

In the latest decades, with the good use of exogenous energy sources, tumor dynamic therapies have been prevailing, such as photodynamic therapy (PDT), sonodynamic therapy (SDT) and chemodynamic therapy (CDT) [183–187]. After site-specific exposure, high level ROS could be generated leading to damage-associated molecular patterns (DAMP) in tumor sites. The accumulation of tumor-associated antigens (TAA) then

---

**Fig. 8.** Multifunctional 3D macroscale scaffolds for combined cancer immunotherapy. (A) The in situ formed fibrin scaffold delivering both cyclophosphamide and aPD-L1 for cancer chemoimmunotherapy to prohibit cancer recurrence at low-immunogenetic surgical site. Reproduced with permission from Ref. [177]. Copyright 2019 WILEY-VCH Verlag GmbH & Co. KGaA. (B) The light-triggered in situ gelation of Ce6-CAT/PEGDA hydrogel enabling repeated stimulations for robust photodynamic-immunotherapy. Reproduced with permission from Ref. [192]. Copyright 2019 WILEY-VCH Verlag GmbH & Co. KGaA.
More singlet oxygen was generated which significantly promoted tumor cell apoptosis, inhibited tumor growth and distant metastasis by means of PDT-mediated immunomodifican improvement [8, B]. To boost personalized immunotherapy, Lei Fang et al. optimized autologous tumor cell-based vaccine (ATV) system with tumor target and on-demand gelation [189]. The ATV using oxidized autologous tumor cells was coated with 9-fluorenyl methoxycarbonyl (Fmoc)-KCRGDK-phenylboronic acid (FK-PBA) hydrogels which could target overexpressed sialic acid on residue tumor cell surfaces. Polyethyl enylamine-conjugated chlorin e6 (PEI-Ce6) in the gels supported the PDT. The peptide-based scaffold could self-assemble into hydrogels in Na2CO3 solution so that the gelation process could be fairly controlled as required. This powerful strategy of engineered ATVs could also provide an alternative avenue for other cell-based antigens to resist specific tumor postoperative relapse.

In addition, photonic hyperthermia-assisted immunotherapy could perform immuno-adjuvant-like effects to mobilize tumor-targeting immunity [194, 195]. The common photothermal immunomodifiers consist of Au-derived nanomaterials, near-infrared (NIR) dye small molecules and others [196, 197]. For example, Tingting Wang et al. came up with a multifunctional personalized idea for postsurgical combined immunotherapy [198]. Tumor-penetrable peptide (Fmoc-KCRGDK) was designed to self-assemble into hydrogels with a BRD4 inhibitor Q1 and indocyanine green (ICG) coloaded. During intratumoral injection, upon the NIR irradiation, ICG as photothermal inducer elevated temperature in tumors to release JQ1 for PD-L1 immune checkpoint blockage and generate tumor-specific antigens by ICD for cancer vaccines. This smart immunotherapeutic hydrogel system established long-term immune-memory and guarded effectively against post-operative tumor relapse and distant metastasis which can also be mirrored in other cancers or different patients. Enci Mei et al. achieved photothermal immunotherapy by an injectable photothermal drug methylene blue (MB) and TLR agonist R837 co-encapsulated collage/n/alginate hydrogel [199]. When eliminating primary tumors, PTT also produced TAAs to gain additive or synergistic immune response with R837 elevating the therapeutic efficiency. Lately, Chao He et al. designed an R837 immune adjuvant-loaded 3D-printing bioglass scaffold. Niobium carbide (Nb2C) MXene as a new kind of thermo-active 2D agents coated with a mesoporous silica layer modified the biodegradable scaffolds [200]. The multifunctional therapeutic scaffold can not only direct immune-activation in TME combined with aPD-L1 ICβ therapy, but also effectively conquer the bone metastasis and even prompt the injured bone regeneration. This system gives a high prospect to solve clinical problems on bone metastasis of breast cancer.

Many other combined therapies have been witnessed in recent few years. The group of Liu Zhuang made good use of aforementioned alginate-Ca2+-in situ gelling system for combinatorial radiotherapy and immunotherapy [201]. With 131I radioisotope labelled CAT for radiotherapy, Cpg ODNs as cancer vaccines and aCTLA-4 antibodies for ICβ therapy, the local treatment has imparted potent systemic antitumor responses in many types of late-stage solid tumors. In the future clinical trials, more therapies, especially like traditional Chinese medicine are anticipated to be took into practice [202].

The shortage of tumor models that resemble the real in vivo TME has greatly slowed down the advancements of cancer immunotherapy into the clinic. Since the humanized in vivo animal model building remains imperfect, a wider range of animal species is urgently demanded, but it puts more pressures onto the costs of both funds and time [20]. The ex vivo 3D scaffolds can be equipped with spatial constructions similar to the physiological microenvironment and permit many exterior controls useful for imitating in vivo human responses or managing dynamic immunocyte activities [52]. The construction of ideal preclinical research model is one of the most crucial steps in immunotherapy.

Natural polymers are very suitable for the preparation of 3D scaffold models. In comparation, the polymers from flora are better than those of fauna origin. Their high repeatability and tunability can make those 3D structures used to study cell-cell interactions with robust reproducibility [203, 204]. Alginate, on behalf of the plant derivatives, is lacking native chemical sites bonding to mammalian cells whose inertness relieves the redundant conditioning of the bioactive media on cell fate. Stephen J. Florczyk et al. developed a 3D chitosan-alginate (CA) scaffold with the goal to study the interactions of cancer cells and lymphocytes in vitro [205]. Evaluated by SEM, immunohistochemistry, confocal fluorescence microscopy and flow cytometry, it was evident to conclude that the CA scaffolds prolonged the co-culture of prostate cancer cells and human peripheral blood lymphocytes for 55 days. They supported the ex vivo interaction of cancer cells with tumor-infiltrating B cells, T lymphocytes, and natural killer cells, and timely supervised in situ for screening immunotherapies, much better than Matrigel or other hydrogels did. Alessandra Marrella et al. also proposed an alginate-derived 3D hydrogel as convenient platform to investigate the neuroblastoma immunization and susceptibility to some unprecedented therapeutics [204]. It can be validated in a reliable way that the cytokine therapy could upregulate the expression of the immune checkpoint ligands on cell surface correlating with NK cell-mediated immune killing.

The acellular scaffolds as naturally derived scaffolds with self-existent 3D networks have revealed initial clinical promise. Some previous studies have confirmed that more engineerability should be employed to that scaffold for promoting the optimal phenotype of the cells [81]. Matthew T. Wolf et al. started a research on whether the immune microenvironment created by the biologic decellularized extracellular matrix, an implanted urinary bladder matrix (UBM) scaffold, encouraged tissue regeneration to develop tumors or not [206]. It was observed that an activated type 2 like wound-healing immune responses potentiated CD4+ T cells and macrophages and affected sensitivety to PD-1 and PD-L1 ICβs, as a signature for tumor inhibition. Therefore, engineering the TME into type 2 wound-healing immune state by 3D scaffolds might improve tumor immunogenicity for targeting.

In addition to in vitro models for the basic studies of oncology, immunology and biology, biomimetic scaffold models as artificial living immune tissues/organs are also imperative for cancers immunorelated tissue engineering [207]. The ex vivo thymus or lymph nodes are anticipated to mimic natural lymphoid organs setting up a site for engineering immunocytes. They can attempt to turn into effective mediators employed for synthetic artificial APCs presenting antigens, generation and expansion of target-reactive effector cells for ACT [101]. However, the structural complexity of the immune organs undoubtedly strengthens the difficulties. Complicated parameters should be individually or collectively taken into concern at various stages. New breakthroughs in immune tissue engineering need to be made for prospective cancer immunotherapy.

5. Conclusions and prospects

Cancer immunotherapy has been universally perceived as a vigorous
force in cancer treatments. To date, anti-cancer immunotherapies have gotten a few exciting grades, whereas some distinct limitations suggest more valid settlements be behaved [208]. The elaborate biomaterial tools with emerging opportunities and potentials provide alternative ways to improve immunotherapeutic outcomes. Many of the delivery strategies delineated are endowed with preload, protection, delivery, and controlled release of imbedded substances. The 3D macroscale biomaterial-assisted delivery technologies can additionally realize local administration and cellular storage. Moreover, the self-assembly of some biomaterials not only offers 3D construction for targeted transportation of cargos, but forms functional matrices for direct anticancer immunity. 3D scaffolds can be further equipped with drugs and external power-responsive agents to mediate dual or triple combinational tumor immunotherapy. Although such cancer immunotherapeutic platforms are just in the infant step, continuous and speedy growth for higher design flexibility will contribute to the broader clinical applications [209,210]. There is a hopeful vision of 3D scaffold-based cancer immunotherapies in the foreseeable future, but there is still a long way to go to address several leftover issues.

First and foremost, the inherent heterogeneity among every individual, different tumors and their district microenvironment is one of the key players that vary the responses to a specific therapeutic regimen [211,212]. Overcoming these limitations requires more detailed understanding of cancer immunobiology, after which the personalized treatment will allow more precise and efficacious immune reactions in the patient. In the recent few decades, a large range of patient-specific genes, signal factors, biomarkers, or neoantigens are long waiting for being discovered and identified [213,214]. The attractive technologies of computer aid and big data information may hasten this development [20].

The tailored biomaterial systems are equally essential for circumventing the failure of immunization. The physiochemical and biological properties of 3D macroscale biomaterials, involving but not limited to mechanical strength and brittleness, volume sensitivity and morphological deformation, viscoelasticity-dependent movement or in situ orientation, biodegradability, and long-term biosafety, deserve further lubrication and optimization [29,59,98]. And the potential in promoting the tumor growth of ECM-like environment should also be concerned. More importantly, how to achieve effective tumor tissue suppression and rapid regeneration of normal tissue in the meantime needs to be emphasized [215]. The research on the property-function relationships of biomaterials themselves could offer many guidelines for the design of 3D materials. Devotions to explaining the mysterious entanglement between immune and material systems seem tremendously requisite. In another words, it must be fully aware of the specific immune response clinically needed to define corresponding immunotherapeutic projects and then objectively analyse the associated organizational feedbacks for tuning design afterwards [210]. Collaboration in the fields of biology, medicine and engineering will improve the universality of 3D scaffold-based tumor immunotherapy.

After immunotherapeutic breadth, the therapeutic depth is another intractable issue. Although 3D scaffolds could solve the problems of nanoparticles hard to infiltrate solid tumors after systematic administration, it may still be a difficulty to accurately insert 3D scaffolds into deep tissues which might require imaging assistant [216]. Besides, the tissue penetration of external stimuli when combinational immunotherapy is also depth-dependent [217,218]. However, the mouse models used in almost all the independent researches are not physiologically analagous to human patients in both size and depth. Therefore, more larger animals should be considered to build up both superficial and deep-seated tumor models at humanlike level, but it is always costly [59,219].

3D macroscale scaffolds can be developed as preliminary researching models. By emulation 3D to 4D modelling of ex vivo immune tissues or organs, the dynamic interaction processes between biomaterials and creatures are possible to be observed in order to facilitate adjustment of several parameters at any time [206,207]. From the aspect of techniques, the leap from 3D printing to 3Dbioprinting technique overturns traditional 3D scaffold preparation [220,221]. Cells such as immunocytes are hoped to be directly used as bio-ink for additive manufacturing [222–224]. What’s more, advanced 4D printing adds a new dimension time based on 3D structures. With smart bioactive materials combined, shapes or functions of 3D bioscaffolds could be transformed over time in response to microenvironmental stimuli. Therefore, dynamic immunotherapeutic intervention at different periods is expected to be achieved [225,226]. However, up to now, the field of model construction and immunotherapeutic applications by this way have rarely been set foot in.

As a product with both clinical transformation significance and commercial transformation value, 3D macroscale scaffolds also need to think about mass production and patient compliance [37,227]. Going forward, the 3D macroscale biomaterial-based immunotherapies with great translational potential will open more avenues of modulating the immune responses against more sophisticated diseases.

Declaration of competing interest

The authors declare no conflicts of interest.

Acknowledgement

This work was supported by the National Natural Science Foundation of China (51973243 and 52173150), National Science and Technology Major Project of the Ministry of Science and Technology of China (2018ZX1005101402), International Cooperation and Exchange of the National Natural Science Foundation of China (51820150004), Guangdong Innovative and Entrepreneurial Research Team Program (2016ZT06S029), Fundamental Research Funds for the Central Universities (1915z33).

References

[1] Q. Sun, M. Barz, B.G. De Geest, M. Diken, W.E. Hennink, F. Kiesling, T. Lammers, Y. Shi, Nanomedicine and macroscale materials in immuno-oncology, Chem. Soc. Rev. 48 (1) (2019) 351–381.
[2] J. Tang, A. Shahabi, V.M. Hubbard-Lacey, Comprehensive analysis of the clinical immuno-oncology landscape, Ann. Oncol. 29 (1) (2018) 84–91.
[3] P.S. Hegde, D.S. Chen, Ten challenges in cancer immunotherapy, Immunity 52 (1) (2020) 17–35.
[4] Z.W. Zhao, L.Y. Zheng, W.Q. Chen, W. Weng, J.J. Song, J.S. Ji, Delivery strategies of cancer immunotherapy: recent advances and future perspectives, J. Hematol. Oncol. 12 (1) (2019).
[5] R.G. Majner, C.L. Mackall, Clinical lessons learned from the first leg of the CAR T cell journey, Nat. Med. 25 (9) (2019) 1341–1355.
[6] O.S. Fenton, K.N. Olafson, P.S. Pillai, M.J. Mitchell, R. Langer, Advances in biomaterials for drug delivery, Adv. Mater. 30 (29) (2018) 1705328.
[7] S.N. Lee, S.M. Jin, H.S. Shin, Y.T. Lim, Chemical strategies to enhance the therapeutic efficacy of toll-like receptor agonist based cancer immunotherapy, Acc. Chem. Res. 53 (10) (2020) 2081–2093.
[8] N.A. Hotaling, L. Tang, D.J. Irvine, J.E. Babensee, Biomaterial strategies for immunomodulation, in: M.L. Yarmush (Ed.), Annual Review of Biomedical Engineering 17, 2015, pp. 317–349.
[9] J.M. Caster, C. Callaghan, S.N. Seyedin, B. Sun, A.Z. Wang, Optimizing advances in nanoparticle delivery for cancer immunotherapy, Adv. Drug Deliv. Rev. 144 (2019) 3–15.
[10] J. Liu, R. Zhang, Z.P. Xu, Nanoparticle-based nanomedicines to promote cancer immunotherapy: recent advances and future directions, Small 15 (32) (2019), 1900262.
[11] R. Toy, K. Roy, Engineering nanoparticles to overcome barriers to immunotherapy, Bioengineering & Translational Medicine 1 (1) (2016) 47–62.
[12] Z. Yang, Y. Ma, H. Zhao, Y. Yuan, B.Y.S. Kim, Nanotechnology platforms for cancer immunotherapy, Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 12 (2) (2020).
[13] Z. Zhao, L. Zheng, W. Chen, W. Weng, J. Song, J. Ji, Delivery strategies of cancer immunotherapy: recent advances and future perspectives, J. Hematol. Oncol. 12 (1) (2019).
[14] J. Nam, S. Son, K.S. Park, W. Zou, L.D. Shea, J.J. Moon, Cancer nanomedicine for combination cancer immunotherapy, Nat. Rev. Mater. 4 (6) (2019) 398–414.
[15] L. Xiao, Y. Huang, Y. Yang, Z. Miao, J. Zhu, M. Zhong, C. Feng, W. Tang, J. Zhou, L. Wang, X. Zhao, Z. Wang, Biomimetic cytomebrane nanovaccines prevent breast cancer development in the long term, Nanoscale 13 (6) (2021) 3594–3601.
Nano- and microscale drug delivery systems for cancer immunotherapy, Acta Biomater. 88 (2019) 15–31.

R.-Z. Tang, Z.-Z. Liu, S.-S. Gu, X.-Q. Liu, Multiple local therapeutics based on nano-hydrogel complexes in breast cancer treatment, J. Mater. Chem. B 9 (6) (2021) 1521–1535.

C. Liu, T. Zhang, L. Chen, Y. Chen, The choice of anti-cancer strategies based on micromotors or drug loading function of biomaterials, Cancer Lett. 487 (2020) 45–52.

A. Fakhari, J.A. Subramony, Engineered in-situ depot-forming hydrogels for intratumoral drug delivery, J. Cont. Release 220 (2015) 465–475.

G. Lesch, S. Young, J.D. Hartperkin, Advances in delivery technology from implantable and injectable biomaterials, Acta Biomater. 88 (2019) 15–31.

W. Wang, Q. Zhang, M. Zhang, X. Li, Z. Li, M. Mohammadnaini, N. Zhou, Y. Sun, A novel biodegradable injectable chitosan hydrogel for overcoming postoperative trauma and combating multiple tumors, Carbohydr. Polym. 265 (2021), 118065.

F.-j. Zhu, Y.-j. Tong, Z.-y. Sheng, Y.-m. Yao, Role of dendritic cells in the host response to biomaterials and their signaling pathways, Acta Biomater. 94 (2019) 532–144.

C. Huang, M. Song, X. Sun, Y. Qu, Y. Man, Collagen membrane and immune response in guided bone regeneration: recent progress and perspectives, Tissue Eng. B Rev. 23 (5) (2017) 421–435.

T. T. Smith, H.F. Moffett, S.B. Stephan, C.F. Ope1, A.G. Dugman, X.Y. Jiang, V. P. Gillisetty, S.P.S. Pillai, K.D. Wittrup, M.T. Stephens, Biopolymers codingerming T cells and Seckin agn voiced eliminate heterogeneous tumors, J. Clin. Invest. 127 (6) (2017) 2176–2191.

A.A. Nada, E.A. All, A.A.F. Soliman, Biocompatible chitosan-based hydrogel with tunable mechanical and physical properties formed at body temperature, Int. J. Biol. Macromol. 131 (2019) 5624–5629.

T. Shafiee, A. A. Aminjonov, A. A. Chaves, A. A. Alioussy, A. A. Smith, T.A. Werfel, Immunostimulatory biomaterials to boost tumor immunogenicity, Biomaterials Science 8 (20) (2021) 5516–5527.

Y. Shi, Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives, Advanced Theraputics 3 (2020) 9.

A.S. Cheung, D.J. Mooney, Engineered materials for cancer immunotherapy, Nano Today 10 (4) (2015) 511–531.

X. You, Z. Gu, J. Huang, Y. Kang, C.C. Chu, J. Wu, Arginine-based poly(ester amide) nanoparticle platform: from structure-property relationship to nucleic acid delivery, Acta Biomater. 74 (2018) 180–191.

M. Choo, S.L. Park, S. Kang, Y. Hong, T. Kwon, S. Kang, Transdermal delivery of therapeutic insulin through the skin, Nanoscale 10 (18) (2018) 7618–7627.

X. Zhang, X. Hong, Q. Shao, T. Y. Zhang, L. Zhang, J. Zhou, J. Xue, M. B. Harris, W. Tao, J.S. Kim, Nanoscale materials-based platforms for the treatment of bone-related diseases, Mater. 4 (9) (2021) 2727–2764.

Z. Tang, N. Kong, X. Zhang, Y. Liu, P. Hou, S. Mou, P. Eilientrom, J. Shi, W. Tan, J. S. Kim, Y. Gao, J. Li, K.W. Leong, W. Tao, A. M. Torza, A materials science perspective on tackling COVID-19, Nat. Rev. Mater. (2020) 1–14.

A.J. Najibi, D.J. Mooney, Cell and tissue engineering in lymph nodes for cancer immunotherapy, Adv. Drug Deliv. Rev. 161 (2020) 42–62.

M.O. Dellacherie, B.R. Sec, D.J. Mooney, Macroscopic biomaterial strategies for local immunomodulation, Nat. Rev. Mater. 4 (6) (2019) 379–397.

O.T. Shofolawe-Bakare, L.D. Stokes, M. Hossain, A.E. Smith, T.A. Werfel, Immunostimulatory biomaterials to boost tumor immunogenicity, Biomaterials Science 8 (20) (2021) 5516–5527.

Y. Shi, Clinical translation of nanomedicine and biomaterials for cancer immunotherapy: progress and perspectives, Advanced Theraputics 3 (2020) 9.
X. Zhang, T.-H. Kim, T.J. Thauland, H. Li, F.S. Majedi, C.L. Sentman, M.T. Stephan, A. McWatters, R. Avritscher, S. Ohtsuki, T. Murakami, M.M. Tan, H. Nakatsuji, S. Ohtsuki, T. Murakami, T. Yata, Y. Takahashi, M.-O. Coppens, R.M. Day, R.M. Day, M. Williams, K. Dixon, C. Dupuis, A. Yang, X. Dong, Y. Bai, S. Sheng, Y. Zhang, T. Liu, D. Zhu, F. Lv, Doxorubicin/CpG self-assembled nanoparticles prodruk and dendritic cells co-loaded hydrogel delivery system, Int. J. Pharm. 547 (2020) 121660.

109. Y. Gong, M. Chen, Y. Tan, J. Shen, Y. Jin, W. Deng, J. Sun, C. Wang, Z. Liu, Q. Chen, Injectable reactive oxygen species-responsive SN38 prodruk scaffold with checkpoint inhibition for combined chemoimmunotherapy, ACS Appl. Mater. Interfaces 12 (42) (2020) 50248–50259.

110. C.G. Park, C.A. Hartl, D. Schmid, E.M. Carmona, H.J. Kim, M.S. Goldberg, Extended release of perioperative immunomodulation prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10 (433) (2018), eaa1916.

111. A. Yang, X. Dong, B. Sai, S. Sheng, Y. Zhang, T. Liu, D. Zhu, F. Lv, Doxorubicin/CpG self-assembled nanoparticles prodruk and dendritic cells co-loaded hydrogel delivery system, Adv. Drug Deliv. Rev. 124 (2018) 1228–1237.

112. T.R. Abreu, A.N. Fonseca, N. Goncalves, J.N. Moreira, Current challenges and emerging opportunities of CAR-T cell therapies, J. Contr. Release 319 (2020) 246–261.

113. B.R. Stephen, A.M. Taber, I. Jileeva, E.P. Pegues, C.L. Sentman, M.T. Stephan, Biopolymer implants enhance the efficacy of adoptive T-cell therapy, Nat. Biotechnol. 33 (1) (2015) 97–U277.

114. Q. Chen, C. Wang, X. Zhang, G. Chen, Q. Hu, H. Li, J. Wang, D. Wen, Y. Zhang, L. Yu, G. Yang, C. Jiang, J. Wang, G. Dotti, Z. Gu, on site sprayed bioreponsive immunotherapeutic gel for post-surgical cancer treatment, Nat. Nanotechnol. 14 (1) (2019) 89–97.

115. Y.Q. Ye, J.Q. Wang, Q.Y. Hu, G.M. Hochu, H.L. Xin, C. Wang, Z. Gu, Synergistic transforming immune responses enhances antitumor immunity through delivery of checkpoint inhibitors, ACS Nano 10 (9) (2016) 8956–8963.

116. Z. Meng, Y. Zhang, J. She, X. Zhou, J. Xu, X. Han, C. Wang, M. Zhu, Z. Liu, Ultrasound-mediated remotely controlled nanovaccine delivery for tumor vaccination and individualized cancer immunotherapy, Nano Lett. 21 (3) (2021) 1228–1237.

117. N. Thanh Loc, Y. Yin, Y. Choi, J.H. Jeong, J. Kim, Enhanced cancer DNA vaccine via direct transfection to host dendritic cells recruited in injectable scaffolds, ACS Macro Lett. 14 (9) (2016) 1218–1222.

118. Z. Luo, Z. Liu, Z. Liang, J. Pan, J. Xu, J. Dong, Y. Bai, H. Deng, S. Wei, Injectable porous microporous with oxygen reservoirs and an immune-niche enhance the efficacy of CAR T cell therapy in solid tumors, ACS Appl. Mater. Interfaces. Interfaces 12 (51) (2020) 25761–25767.

119. C.A. Reinhart-King, Targeting tissue stiffness in metastasis: mechanomedicine improves cancer therapy, Cancer Cell 37 (6) (2020) 755–775.

120. H. Ruan, L. Bu, Q. Hu, H. Cheng, W. Lu, Z. Gu, Strategies of combination drug delivery for immune checkpoint blockades, Adv Healthc Mater 8 (4) (2019), e1801099.

121. Y. Shi, D. Li, C. He, X. Chen, Design of an injectable polypeptide hydrogel depot containing the immune checkpoint blocker anti-PD-1 and doxorubicin to enhance antitumor combination therapy, Macromol. Biosci. 21 (6) (2021), 2100049.

122. L. Li, Z. Yang, X. Chen, Recent advances in stimuli-responsive platforms for cancer immunotherapy, Acc. Chem. Res. 53 (10) (2020) 2044–2054.

123. D. Li, R. Zhang, G. Liu, Y. Kang, J. Yu, Redox responsive self-assembled nanoparticles for cancer therapy, Adv. Healthcare Mater. 9 (20) (2020), e2000605.

124. Z.M. Zhao, A. Ukived, A. Daugspa, S. Miragoli, Targeted immunomodulation: principles, advances and perspectives, Adv. Drug Deliver. Rev. 127 (2018) 3–19.

125. H. Ruan, Q.Y. Hu, D. Wen, Q. Chen, G. Chen, Y.F. Lu, J.Q. Wang, H. Cheng, W. Yu, L. Zhu, A dual-bioreponsive drug-delivery depot for combination of epigenetic modulation and immune checkpoint blockade, Adv. Mater. 31 (17) (2019), 1806057.

126. S.B. Stephan, A.M. Taber, I. Jileeva, E. Pugh, C.L. Sentman, M.T. Stephan, Generation of therapeutic immune responses, Adv. Drug Deliv. Rev. 114 (2017) 3823–3835.

127. T.R. Abreu, N.A. Fonseca, N. Goncalves, J.N. Moreira, Current challenges and emerging opportunities of CAR-T cell therapies, J. Contr. Release 319 (2020) 246–261.

128. N.J. Shah, A.J. Najibi, T.Y. Shih, A.S. Mao, A. Sharda, D.T. Scadden, D.J. Mooney, An immunobiologic-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia, Nat Biomed Eng 4 (1) (2020) 40–51.

129. S.A. Bencherif, R. Warren Sands, O.A. Ali, W.A. Li, S.A. Lewin, T.M. Brachler, T.Y. Shih, C.S. Verbeke, D. Bhattachar, G. Dranoff, D. Mooney, Injectable gelayer-based whole-cell cancer vaccines, Nat. Commun. 6 (2015) 7556.

130. Y.Q. Ye, C. Wang, X.X. Zhang, Q. Mei, Y.Q. Zhang, Q. Lu, D. Li, J. Milligan, A. Bellotti, L. Huang, G. Dotti, Z. Gu, A melanin-mediated cancer immunotherapy patch, Science Immunology 2 (17) (2017), eaan6592.

131. Y. Yin, X. Li, H. Ma, J. Zhang, D. Yu, R. Zhao, S. Yu, G. Nie, H. Wang, In situ transforming DNA nanomaterials to generate a self-assembled nanogel to mediate estrogen receptor positive breast cancer chemoresistance, Nano Lett. 21 (5) (2021) 2224–2231.

132. Z.T. Sun, J. Liang, X. Dong, C.W. Kong, L. F. Lv, Injectable hydrogels co-crosslinking granulocyte-macrophage colony-stimulating factor and ovalbumin nanoparticles to enhance antigen uptake efficiency, ACS Appl. Mater. Interfaces. Interfaces 10 (24) (2018) 20315–20325.

133. F. Yang, K. Shi, Y. Ji, C. Zhang, L. Yuan, Y. Chen, M. Pan, Z. Qian, A biodegradable theragenic hydrogel vaccine for cancer immunotherapy, Applied Materials Today 19 (2020), 100608.

134. J.J. Havel, D. Chowell, T.A. Chan, The evolving landscape of biomarkers for checkpoint inhibition immunotherapy, Nat. Rev. Cancer 19 (3) (2019) 133–150.

135. S. Han and J. Wu
[134] Z. Yu, Y. Xu, H. Yao, X. Si, G. Ji, S. Dong, J. Zhao, Z. Tang, X. Fang, W. Song, X. Chen, A simple and general strategy for post-surgical personalized cancer vaccine therapy based on an injectable dynamic covalent hydrogel, Biomater. Sci. 9 (2021) 6879–6888.

[135] A. Yang, Y. Bai, X. Dong, T. Ma, Z. Zhu, L. Mei, F. Li, Hydrogel-nanodrug-mediated combined cell vaccines for cancer immunotherapy, Acta Biomater. 133 (2021) 257–269.

[136] X. Liu, Z. Feng, C. Wang, Q. Su, H. Song, C. Zhang, P. Huang, X. J. Liang, A. Dong, D. Kong, W. Wang, Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses, Biomater. Sci. (2020) 230.

[137] Y.H. Ahn, L. Ren, S.M. Kim, S.H. Seo, C.R. Jung, D.S. Kim, J.Y. Noh, S.Y. Lee, H. Lee, M.Y. Cho, H. Jung, S.R. Yoon, J.E. Kim, S.N. Lee, S. Kim, L.W. Shin, H. S. Min, K.S. Hong, J. Yi, C. Huh, Nanofibrous hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy, Biomaterials 247 (2020) 119960.

[138] P. Agarwalla, E.A. Ogunmase, S. Ahn, F.S. Ligler, G. Dotti, J. Brudno, Scaffold-mediated static transfection of T cells for CAR-T cell therapy, Advanced Healthcare Materials 9 (14) (2020) 2000275.

[139] J. Weiden, D. Voerman, Y. Dolen, R.K. Das, A. van Duffelen, R. Hammink, L. J. Eggemont, A.E. Rowan, J. Tel, C.G. Figdor, Injectable biomimetic hydrogels as tools for efficient T cell expansion and delivery, Front. Immunol. 9 (2018) 2796.

[140] H.L. Lin, W. Yang, Y.H. Huang, W.T. Liao, T.Y. Lin, S.Y. Lin, D.Z. Liu, Decellularized lymph node scaffolding as a carrier for dendritic cells to induce anti-tumor immunity, Pharmaceuticals 11 (10) (2019) 538–548.

[141] J. Zhang, C. Chen, A. Li, W. Jing, P. Su, X. Huang, Y. Liu, S. Zhang, W. Du, R. Zhang, Y. Liu, A. Gong, J. Wu, X. Jiang, Immunosuppressor hydrogel for the inhibition of malignant glioma relapse post-resection, Nat. Nanotechnol. 16 (2021) 538–548.

[142] Q. Hu, H. Li, J. Che, H. Chen, M. Ichinose, Q. Chen, H. Ruan, A. Ahn, E. Archibong, Q. Chen, H. Ruan, S. Ahn, E. Dukhovlinova, Y. Kang, J.W. Hickey, Y. Dong, J.W. Chung, S.F. Salathe, H.C. Pruitt, X.W. Li, C. Chang, A.D. Guerra, O.W.H. Yeung, X. Qi, W.J. Kao, K. Man, The anti-tumor effects of M1 hydrogelator as an immune booster for checkpoint blocker-based cancer immunotherapy, Biomaterials 6 (11) (2021) 3924–3934.

[143] Y. Shi, Z.M. Yang, A strong CD8(+) T cell response induced by the anti-inflammatory hydrogelator, Adv. Funct. Mater. 30 (4) (2020), 1906253.

[144] G. Sikora, J.D. Hartgerink, S. Young, Biomaterial-facilitated immunotherapy for cancer, Mater. Interfaces 10 (11) (2018) 9310–9323.

[145] Q. Chen, M. Chen, Z. Liu, Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor response, Chem. Soc. Rev. 48 (22) (2019) 5506–5526.

[146] F. Yang, K. Shi, Y. Hao, J. Yin, Q. Liu, Y. Chen, M. Pan, L. Yuan, Y. Yu, Z. Qian, Cyclophosphamide loaded thermo-responsive hydrogel system synergizes with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner, Bioactive Materials 6 (10) (2021) 3036–3048.

[147] X. Xiong, J. Zhao, R. Su, C. Liu, X. Guo, S. Zhou, Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy, Nano Today 39 (2021), 101225.

[148] M. Liu, Z. Cao, R. Zhang, Y. Chen, X. Yang, Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemotherapy, Adv. Mater. Interfaces 13 (2020) 33847–33848.

[149] Y. Zhang, Y. Li, F. Meng, H. Li, H. Zhang, J. Tu, C. Sun, L. Luo, Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer gel matrix for post-surgical treatment of breast cancer, Nano-Micro Lett. 13 (1) (2021) 1–11.

[150] Q. Lv, C.L. He, F.L. Quan, S.J. Yu, X.S. Chen, DOX/IL-2/IFN-gamma co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment, Bioactive Materials 3 (1) (2018) 118–128.

[151] L. Jiang, Y. Ding, X.L. Xue, X.S. Zhao, C. Li, X.R. Zhang, Q.X. Jiang, Entrapping multifunctional dendritic nanoparticles into a hydrogel for local therapeutic delivery and synergetic immunotherapy, Nano Res. 11 (11) (2018) 6062–6073.

[152] F. Vishwiva, L.E. Milling, Q. Chen, W. Zhang, S. Bhagchandani, H.V.T. Nguyen, D. J. Irvine, J.A. Johnson, ABCtiblock bottlebrush copolymer-based injectable hydrogelic design, synthesis, and application to expanding the therapeutic index of cancer immunotherapeutics, Adv. Mater. 33 (23) (2021) 5974–5986.

[153] C. Wang, J.Q. Wang, X.D. Zhang, S.J. Yu, D. W, Q.Y. Hu, Y.Q. Ye, H. Bomba, X. Lu, H. Liu, G. Dotti, Z. Gu, In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy, Sci. Transl. Med. 10 (429) (2018), eaar3682.

[154] H.W. Huang, A.Ji. Najibi, M.C. Sobral, B.R. Seo, J.Y. Lee, D. Wu, A.W.Li, C. Verbeke, D.J. Mooney, Biomaterial-based scaffold for in situ chemotherapy and immunotherapy to treat poorly immunogenic tumors, Nat. Commun. 11 (1) (2020) 5696–5706.

[155] L. Sun, F. Shen, L. Tian, H. Hao, Z. Xiong, J. Xu, Z. Liu, ATP-responsive smart hydrogel releasing immune adjuvant synthesized with repeated chemotherapy or radiotherapy to boost antitumor immunity, Adv. Mater. 33 (18) (2021), 2007910.

[156] L. Zhang, J.H. Zhou, L.Z. Hu, X. Han, X.W. Zou, Q. Chen, Y.G. Chen, Z. Liu, C. Wang, In situ formed fibrin scaffold with cyclodextrin to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery, Adv. Funct. Mater. 30 (7) (2019), 1906202.

[157] K. Ueda, J. Akiba, S. Ogasawara, K. Todoroki, M. Nakayama, A. Sumi, H. Kusano, S. Sanada, S. Suekane, K.M. Xu, K.H. Bae, M. Kurisawa, T. Igawa, H. Yano, Growth inhibition of an injectable hyaluronic acid-tyramine hydrogel by injecting plasmid DNA, Adv. Healthcare Materials 3 (10) (2014) 1101–1111.

[158] H. Phuangkham, C. Song, S.H. Um, Y.T. Lim, Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy, Adv. Mater. 30 (18) (2018), 1706719.

[159] T. Baultois, R.M. Toy, S.H. Mababhat, A.J. Najibi, A.S. Mao, D. Liu, P. Garan, H.A. Santos, B. Sarmiento, D.J. Mooney, Acetlated dextran nanoparticles loaded with IL-2 or IL-12 can be used as a combination chemotherapy and cancer vaccination, Adv. Funct. Mater. 29 (35) (2019) 190386.

[160] C.L. Yu Hao, Huiquan Tao, Yaran Du, Xi Wang, Jialing Dong, Quanlong Jin, Shaoqiong Chen, Jun Xu, Zhanglei Xiao, Qian Chen, Chao Wang, Jian Zhang, Zhuling Liu, Localized cocktail chemoinmunotherapy after in situ gelation to boost robust systemic antitumor immune response, Sci. Adv. 6 (2020), eaaz5054.

[161] H. Zhao, Q. Song, C. Zheng, B. Zhao, L. Wu, Q. Feng, Z. Zhang, L. Wang, Implantable bioreactive nanooarray enhances postsurgical immunotherapy by activating pyroptosis and remodeling tumor microenvironment, Adv. Funct. Mater. 30 (51) (2020), 2005747.
